Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Non-Current Liabilities (2016 - 2025)

Sutro Biopharma's Other Non-Current Liabilities history spans 10 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities changed 0.0% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, changed 0.0%, while the annual FY2024 figure was $1.7 million, 0.0% changed from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $1.7 million at Sutro Biopharma, roughly flat from $1.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q4 2023 and bottomed at $119000.0 in Q4 2022.
  • The 5-year median for Other Non-Current Liabilities is $1.6 million (2021), against an average of $1.1 million.
  • The largest annual shift saw Other Non-Current Liabilities crashed 91.16% in 2022 before it soared 1323.53% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $146000.0 in 2021, then decreased by 18.49% to $119000.0 in 2022, then skyrocketed by 1323.53% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Other Non-Current Liabilities are $1.7 million (Q3 2025), $1.7 million (Q2 2025), and $1.7 million (Q1 2025).